Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of two different surgical techniques with prf in the treatment of multiple gingival recessions

Conditions: Gingival Recession

Summary: this prospective clinical study aims to evaluate and compare the effectiveness of coronally advanced flap (caf) and tunnel techniques, both combined with platelet-rich fibrin (prf), in the treatment of multiple miller class i-ii gingival recessions. eleven participants with bilateral defects will be treated using a split-mouth design. periodontal parameters will be assessed at baseline, 3 months, and 6 months.

the objective of this prospective clinical trial is to compare two mucogingival surgical techniques-coronally advanced flap (caf) and tunnel technique-used in combination with platelet-rich fibrin (prf) for treating multiple miller class i-ii gingival recessions. eleven systemically healthy participants with bilateral gingival recessions will be enrolled. caf+prf will be applied on one side, and tunnel+prf on the contralateral side. clinical parameters including plaque index, gingival index, bleeding on probing, probing depth, clinical attachment level, recession height and width, and keratinized tissue height will be recorded at baseline, 3 months, and 6 months. root coverage outcomes and clinical attachment gain will be analyzed.

Eligibility criteria:
inclusion criteria: * age 18 years or older * systemically healthy individuals * presence of bilateral miller class i-ii multiple gingival recessions * good oral hygiene and willingness to follow instructions * signed informed consent exclusion criteria: * use of tobacco or smoking * pregnancy or lactation * presence of systemic diseases affecting periodontal health * use of medications that may affect healing (e.g., corticosteroids) * periodontal surgery in the same area within the last 6 months

Keywords: gingival recessions platelet rich fibrin root coverage
evaluation of the quality of life questionnaire-bronchiectasis (qol-b) in patients with bronchiectasis

Conditions: Bronchiectasis

Summary: over the 70-day study period, eligible patients visited the study clinic every 2 weeks (total of 6 visits) and received a 28-day course of aztreonam for inhalation solution (azli). the quality of life-bronchiectasis (qol-b) questionnaire was completed at several time points during the study, in additional to pulmonary function testing and other standard procedures.


Eligibility criteria:
inclusion criteria: * written informed consent prior to any study-related procedures * ability to read and understand the english language * bronchiectasis confirmed by ct scan of the chest * previous treatment with antibiotics for bronchiectasis * documented history of positive sputum culture for a gram-negative organism within 5 years * positive sputum culture for a gram-negative organism at first visit (day -14) exclusion criteria: * hospitalization or hemoptysis \> 30 ml within 14 days of first visit (day -14) * antibiotic use for respiratory symptoms within 14 days of first visit (day -14), excluding chronic, stable azithromycin use * change in corticosteroid or bronchodilator regimen within 14 days of first visit (day -14) * forced expiratory volume in 1 second (fev1) \< 25% predicted approximately 15 minutes following use of a bronchodilator at first visit (day -14) * cigarette smoking within 6 months of first visit (day -14)
study assessing patient satisfaction with latisse® for increasing eyelash prominence

Conditions: Hypotrichosis

Summary: the purpose of this study is to determine patient satisfaction with latisse® treatment for increasing eyelash prominence.


Eligibility criteria:
inclusion criteria: * have inadequate eyelashes * never used prescription eyelash growth products exclusion criteria: * no visible eyelashes * permanent eyeliner or eyelash implants * semi-permanent eyelash tint, dye, or extensions within 3 months * over-the-counter eyelash growth products within 6 months * any disease, infection or abnormality of the eye or area around the eye * eye surgery within 3 months, or the anticipated need for eye surgery during the study * unable or unwilling to keep contact lenses out during drug application and for 30 minutes after application
the incidence of postoperative re-stratification for recurrence in well-differentiated thyroid cancer - a single tertiary israeli center experience

Conditions: Well Differentiated Thyroid Carcinoma; Papillary Thyroid Cancer

Summary: background after diagnosing well-differentiated thyroid cancer (wdtc), careful assessment of the risk for disease-specific recurrence is essential for deciding between partial (low risk) and completion (high risk) thyroidectomies. patients' preoperatively determined risk levels are re-stratified according to surgical and final histopathological findings. the american thyroid association 2015 guidelines suggest that patients with wdtc between 1-4 cm in size and without suspicious features may be suitable candidates for partial thyroidectomy. the incidence and clinical implications of high-risk features discovered postoperatively in patients with preoperatively determined low-risk wdtc have not been previously reported. methods all thyroidectomies performed between 2006-2018 in the tel aviv sourasky medical center were included. pre- and postoperative risk stratifications were performed, and the rate of completion thyroidectomy was determined. patients with 1-4 cm wdtc without evidence of positive cervical lymph nodes, invasion to adjacent structures, or high-risk cytology were considered at low risk for disease-specific recurrence and therefore suitable for lobectomy.


Eligibility criteria:
inclusion criteria: * all patients who underwent thyroid surgery (partial and total) between 2006-2018 at tel aviv sourasky medical center (tasmc) were included exclusion criteria: * patients with evidence of cervical lymph node metastasis, other malignancies, adverse imaging features (i.e., extracapsular spread of thyroid malignancy, vocal cord paralysis or immobility in physical examination) were excluded from the study.

Keywords: low risk, risk stratification, partial thyroidectomy, hemithyroidectomy, completion thyroidectomy
optigon - optimising laboratory assays for immune responses to gonococcus

Conditions: Gonorrhea

Summary: this is an observational study. blood from otherwise healthy patients presenting with confirmed n.gonorrhoea infection, prior to treatment, will be collected to (i) allow the optimisation of assays assessing the immune response to gonococcus and (ii) assess whether n. gonorrhea specific responses can be detected on elispot +/- flow cytometry. the investigators plan to recruit up to 30 adults (men and women, aged 18-50 years) who have been diagnosed with confirmed n.gonorrhoea infection at the sexual health clinic at the oxford university hospitals nhs foundation trust. the investigators will collect blood samples from consenting participants prior to them receiving curative antibiotic treatment.

on the day the patient attends the sexual health clinic, they will be given the pis to consider participation to the study following a confirmed positive result for n. gonorrhoea infection. following written informed consent, a venous blood sample will be collected (up to 26 ml) on the same day. this will conclude that participant's involvement to the study. the blood sample will be transported to the laboratory at the jenner institute, university of oxford for further analysis.

Eligibility criteria:
inclusion criteria: * adults (18-50 years) attending oxford university hospitals nhs foundation trust with untreated confirmed n. gonorrhoea infection confirmed by either: * nucleic acid test * microscopy of urethral discharge exclusion criteria: * have already received antimicrobial therapy to treat the n. gonorrhoea infection * have not provided written, informed consent. * presence of any known medical condition which, in the opinion of the local investigator, makes the donation of 26 mls of blood unsafe.
a safety and efficacy study in subjects with diabetic neuropathic pain

Conditions: Diabetic Neuropathic Pain

Summary: the purpose of this study is to evaluate the safety and efficacy of a 6 mg twice a day dose of an investigational product in subjects with diabetic neuropathy


Eligibility criteria:
inclusion criteria: * males and females, age 18 to 75 * if female, must be of non-childbearing potential or practicing birth control * has diabetes mellitus (type 1 or 2) and a diagnosis of painful distal symmetric diabetic polyneuropathy * has had pain from distal symmetric diabetic polyneuropathy for a minimum of 6 months * must be willing to washout of all analgesic medications prior to entry into the study exclusion criteria: * has other conditions that may cause pain * currently receiving analgesic medications for conditions other than diabetic neuropathic pain * has a history of certain psychiatric diseases * has a history of certain heart or cardiovascular conditions * has any clinically significant recent infection, injury, or illness * current participation in another clinical study or participation within the past 30 days * is incapacitated, bedridden or confined to a wheelchair * is pregnant and/or breastfeeding * previous participation in this study or any other study with this investigational product.
using covered stent of diameter of 7mm in tips

Conditions: Liver Disease

Summary: this study evaluates the incidence of hepatic encephalopathy between covered stent of diameter of 7mm and 8mm in tips(transjugular intrahepatic portosystemic stent shunt ).half of the participants will receive stent of diameter of 7mm ,while the other half will receive stent of diameter of 8mm.

tips is effective in the treatment of hemorrhage of digestive tract and intractable ascites,which are the complications of cirrhosis. at present, the high incidence of hepatic encephalopathy has been a major problem after tips. the high incidence rate of hepatic encephalopathy was closly associated with the diameter of the stent. we often use the stent of diameter 8mm in tips.in this study, we try to use the stent of smaller diameter of 7mm in tips,and compare the incidence of hepatic encephalopathy between the stent of diameter of 7mm and 8mm .

Eligibility criteria:
inclusion criteria: 1. there is a clear tips treatment indications of liver cirrhosis portal hypertension patients of gastrointestinal bleeding. 2. undergoing elective tips to treat patients. 3. aged 18-70 years old exclusion criteria: 1. preoperative patients with hepatic encephalopathy. 2. with portal vein thrombosis patients. 3. combined liver malignant tumor or other parts of the patients with malignant tumor. 4. in combination of peptic ulcer bleeding.

Keywords: transjugular intrahepatic portosystemic shunt
effects and mechanisms of ras training on upper-limb movements in pd patients

Conditions: Acoustic Stimulation; Parkinson Disease; Electroencephalography

Summary: introduction bradykinesia (i.e., slow movements) is one of the most prominent symptoms of parkinson's disease (pd) and has a negative impact on quality of life. rhythmic auditory stimulation (ras), a widely used and promising treatment technique, has been shown to effectively improve gait speed in pd patients. however, only few studies have explored effects and neural mechanisms of ras on upper-limb movements. we will conduct two studies to investigate effects and mechanisms of ras on upper-limb movements in pd patients. the purpose of this study is to examine effects and neural mechanisms of upper-limb movement training involving ras in pd patients. methods this study will recruit patients with pd and healthy controls. this study will randomly assign pd patients into two groups: the pd-ras group and the pd-noras group, and healthy controls into the hc-ras group and the hc-noras group. a 7-day upper-limb training involving ras (for the pd-ras group and the hc-ras group) or without ras (for the pd-noras group and the hc-noras group) will be provided. eeg and behavioral assessments will be conducted before and after the first day of training, and after the seven-day training program. two-way repeated measures analysis of variance will be performed to investigate the group and time effects on upper-limb function and neural activity. study significance the training program will serve as a reference for clinical practitioners who are interested in using ras in clinical training for pd patients.


Eligibility criteria:
inclusion criteria: * (a) idiopathic pd diagnosed by a neurologist based on the movement disorders society clinical diagnostic criteria; * (b) the hoehn and yahr stage is 2 or 3, meaning that bilateral movement problems or combination with mild postural instability; * (c) a score of montreal cognitive assessment (moca) is equal to or higher than 21 to ensure that they understand experimental instructions; * (d) a score of edinburgh handedness inventory is above 60 to ensure that they are right-handed; * (e) types and doses of medications remain unchanged in the past month right before participation. * age- and sex-matched healthy controls who filled the criteria (c) and (d) will be recruited from communities. exclusion criteria: * the presence of medical conditions or diseases that may affect hand movements, vision, or hearing based on self-report.

Keywords: acoustic stimulation parkinson disease movement electroencephalography
medication treatment for depression in nursing home residents

Conditions: Depression

Summary: this study will examine therapeutic and adverse effects of continuing versus discontinuing antidepressant medication in nursing home residents who have had no more than a single episode of depression and who no longer have depressive symptoms.

there are approximately 1.6 million nursing home residents in the united states. more than one third of these residents are taking antidepressant medications (ads). although ads are effective, evidence suggests that they can lead to significant adverse events, including an increased risk of falls and bone fractures. many depressed nursing home residents suffer from an initial episode of late-life depression and do not meet guideline-based recommendations for maintenance treatment. this study will examine the benefits and risks of long-term ad treatment in depressed nursing home residents whose single episode of depression has been in continuous remission for at least six months. participants will be randomly assigned to either continue or discontinue ad treatment. participants will be monitored over a period of one year for recurrence of depression and related symptoms, as well as for the occurrence of falls, fractures, and other adverse events. medical chart review, self-reported mood symptoms, and depression scales will be used to assess participants.

Eligibility criteria:
inclusion criteria: * current use of antidepressant medication * have been in remission from first episode of depression for 6 months or longer * currently residing in a long term care or assisted living facility exclusion criteria: * bedridden * severe cognitive impairment

Keywords: antidepressant drugs nursing homes
changing dietary patterns: an individually tailored nutrition intervention (oke-study)

Conditions: Obesity

Summary: the main objective of this study is to investigate the effect of a personalized nutrition intervention on the dietary pattern of apparently healthy adults with one or more children aged 4 to 12 years.

giving personalized nutrition advice is perceived to be more effective in changing dietary patterns than giving general information about healthy eating.

Eligibility criteria:
inclusion criteria: * at least aged 18 years * having one child aged 4 to 12 years * written informed concent has been obtained exclusion criteria: * not meeting the inclusion criteria * unable or unwilling to comply with the study procedures * enrolled in another study during the same study period * not being able to communicate (read, speak and write) in the dutch language * having a partner who has been enrolled in the study * being pregnant or lactating during the study period or planning to become pregnant during the study period * having a bmi lower than 18.5 or higher that 35 kg/m2 * using medication to lower cholesterol or being under control by a doctor for having too high cholesterol levels * using medication to lower blood pressure or being under control by a doctor for having a high blood pressure. * having diabetes type i or type ii * following a diet (medical or self-initiated) or planning to follow a diet during the study period * undergoing a medical treatment that interferes with the intervention. * having gained or lost more than 5 kg of body weight during the last 6 months.

Keywords: health promotion dietary counseling
mostafa maged technique to control and prevent the post-partum bleeding from the lower uterine segment in placenta previa cases

Conditions: Placenta Previa

Summary: post - partum haemorrhage is still a headache to all obstetricians around the whole world . every obstetrician exerts his own full effort to control bleeding which can occur post-partum by applying all maneuvers to preserve the fertility and the uterus for the patient . demonstration of ( mostafa maged ) technique is applied to control and prevent post-partum haemorrhage . it is so simple maneuver and easy to be applied within short period of time .satisfactory hemostasis can be assessed after application .

1. pfannestiel incision . 2. dissection of the bladder downwards , and then making an incision in the lower segment of the uterus , then the uterus is evacuated from the fetus and placenta . 3. ligation of the uterine arteries on both sides is applied before proceeding and after the extraction of fetus and placenta . 5) the lower segment was bleeding so trying to do bimanual compression of the anterior and posterior parts of lower uterine segments to test if mostafa maged technique is useful in these cases or not (( by observing if the bleeding is minimized or stopped or not by compression )) as if it is minimized so our technique has a high chance to be effective . 6) the whole technique depends on the anterior lower uterine segment by dividing the anterior lower uterine segment by an imaginary line in two halves , then , turning over (flipping ) the upper part of the lower uterine segment onto the lower part of the lower uterine segment from the inside of uterine cavity . 7) doing this turnover (flipping ) by the hands and holding the imaginary line by two allis forceps and by making three knots by three needles in the lower edge of the uterine incision and entering the needles of (absorbable 70 mm rounded-bodied vicryl 1 ) simultaneously into the lower segment through the uterine cavity , at the same level of , the inside wall of lower uterine segment in order to drag the upper (half) part of the lower uterine segment on the lower part of lower uterine segment ( sandwich - like ) , and after this maneuver the bleeding is re-evaluated again . 8) third , stitching the both sides of the flipped lower uterine segment by ( absorbable 70 mm rounded-bodied vicryl 1 ) , then doing plication of the anterior lower uterine segments to strengthen the wall of the flipped lower uterine segment and secure the tension . 9) fourth , closing the caeserian scar by suturing the already-flipped lower uterine segment onto the upper uterine segment . 10) placing a drain in the doglus pouch

Eligibility criteria:
inclusion criteria: * pregnant primigravida patients with placenta previa * 18 to 30 years old exclusion criteria: * patients with bleeding disorders * smokers * morbid obese patients

Keywords: mostafa maged technique placenta previa lower uterine segment caeserian section
a study to evaluate kin-3248 in participants with advanced tumors harboring fgfr2 and//or fgfr3 gene alterations

Conditions: Solid Tumor, Adult; Intrahepatic Cholangiocarcinoma; Urothelial Carcinoma

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (pk), and preliminary efficacy of kin-3248, an oral small molecule fgfr inhibitor, in adults with advanced tumors harboring fgfr2 and/or fgfr3 gene alterations.

this is a two-part, open label, multi-center, dose escalation and dose expansion study in participants with advanced tumors harboring fgfr2 and/or fgfr3 gene alterations. part a (dose escalation) is aimed at evaluating the safety, tolerability, pharmacokinetics (pk), and pharmacodynamics (pd) of kin-3248, and determining the maximum tolerated dose (mtd) of daily dosing of kin-3248. part b (dose expansion) may open once either the mtd and/or a biologically active dose of kin-3248 is identified. part b is aimed at evaluating the safety and efficacy of kin-3248 at the recommended dose and schedule in participants with cancers harboring fgfr2 and/or fgfr3 gene alterations, including intrahepatic cholangiocarcinoma (icc), urothelial cancer (uc), and other solid tumors.

Eligibility criteria:
inclusion criteria: * provide written informed consent prior to initiation of any study-specific procedures * advanced stage solid tumor * known fgfr2 and/or fgfr3 gene alteration, as confirmed by previous genomic analysis of tumor tissue or ctdna * measurable or evaluable disease according to recist v1.1 * ecog performance status 0 or 1 * adequate organ function, as measured by laboratory values (criteria listed in protocol) * able to swallow, retain, and absorb oral medications exclusion criteria: * known clinically-active or clinically-progressive brain metastases from non-brain tumors * history and/or current evidence of abnormal calcium-phosphorous homeostasis, ectopic mineralization or calcification, or corneal or retinal disorder/keratopathy * gi tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory gi disease * active, uncontrolled bacterial, fungal, or viral infection * women who are lactating or breastfeeding, or pregnant

Keywords: fgfr inhibitor targeted therapy fgfr2 alteration fgfr3 alteration secondary resistance fgfr alteration